Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Daclizumab (compound)


PubChem Substance
Name: daclizumab
PubChem Substance ID: 17397742
Synonyms:
D03639; Daclizumab; 152923-56-3; Daclizumab (USAN); Zenapax (TN); Zenapax
DrugBank
Identification
Name: daclizumab
Name (isomeric): DB00111
Drug Type: biotech
Synonyms:
Ig gamma-1 chain C region; Humanized antiCD25; Anti-IL-2
Brand: Zenapax (Hoffmann-La Roche Inc)
Category: Immunomodulatory Agents, Immunosuppressive Agents
CAS number: 152923-56-3
Pharmacology
Indication: Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
Pharmacology: Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Mechanism of Action: Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes.
Half Life: 11-38 days
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Targets